Emerging Infections Programs

Active

Assistance listing
93.317
Agency
Grant awards
46 $2,468,824,899 in federal obligations

Program facts

Assistance types
  • Project Grant
  • Cooperative Agreement
Treasury account
  • 75-0949-0-1-550
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The Centers for Disease Control and Prevention (CDC) funds active infectious disease surveillance, applied epidemiologic and laboratory activities, pilot prevention and intervention projects, and rapid response to emerging infectious disease threats under the Emerging Infections Programs (CFDA 93.317), with the most recent grant awards made in September 2024.

The program distributes $2.4 billion in combined federal obligations across 42 awards since 2012, with award activity accelerating in recent years: 14 awards in 2024, 13 in 2022, compared to 2 in 2021 and 6 in 2017. Awards are predominantly Cooperative Agreements (83 percent) with smaller shares of Project Grants (17 percent), and all funding flows through CDC. The portfolio includes major multi-million-dollar awards alongside smaller specialized grants. Recent examples include New Mexico's Emerging Infections Program ($21.1 million for surveillance spanning respiratory viruses, foodborne diseases, healthcare-associated infections, and antimicrobial resistance across state and bordering areas), Minnesota's EIP continuation ($17.9 million for core surveillance functions including influenza, COVID-19, RSV, foodborne pathogens, and tickborne disease), and Arkansas's Epidemiology and Laboratory Capacity award ($2.8 million supporting 41 positions for acute infectious disease work). The program also funds specialized surveillance efforts such as tracking post-COVID-19 conditions in diverse populations and nationwide blood donor cohorts for respiratory virus burden estimation.

Recipients are state and local health departments, the District of Columbia, U.S. Territories, and academic or nonprofit partners collaborating with public health agencies. Projects run for up to five years with 12-month budget periods. Allowable costs include personnel, travel, supplies, and contractual services supporting surveillance systems, laboratory infrastructure, data modernization, and emergency response capacity.

The most recent solicitation CDC-RFA-CK24-2401 for the Emerging Infections Program closed in June 2023 and produced the August 2024 awards shown in the portfolio. A new opportunity, CDC-RFA-CK-25-0144, opened August 22, 2024 (due March 18, 2025) for Creutzfeldt-Jakob Disease educational support to families and healthcare providers, addressing prion disease and chronic wasting disease emergence. The program evaluates applications on capacity to perform core EIP functions, proposed operational plans, and effectiveness measures; successful applicants proceed to non-competitive annual continuation funding within the project period subject to satisfactory progress and available funding.

Objective and description

Objective

The purpose of the Emerging Infections Programs (EIP) is to assist in local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. The EIP cooperative agreement was formed in 1995 as a key compo

Description

The EIP network assists with local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. Activities of the EIP network fall into the following overall categories: (1) active infectious disease surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) rapid and flexible response to public health emergencies and newly emerging issues for infectious diseases.

Eligibility

Beneficiary eligibility

Beneficiaries of this program include State and local health departments, the District of Columbia, U.S. Territories, and the general public.

Uses of assistance

Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual. Funding under this program will support activities that fall within the following general activities: (1)active surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) flexible response to public health emergencies. Activities: (1) address issues that the EIP network is particularly suited to investigate; (2) maintain sufficient flexibility for emergency response and new problems as they arise; (3) develop and evaluate public health interventions to inform public health policy and treatment guidelines; (4) incorporate training as a key function; and (5) prioritize projects that lead directly to the prevention of disease (http://wwwlink.cdc.gov/ncezid/dpei/eip).

Length and time phasing of assistance

Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient.

How to apply

Criteria for selecting proposals

Applications are reviewed against specific Evaluation Criteria published in the Notice of Funding Opportunity for this program. Evaluation Criteria in the most recently published NOFO include: (1) capacity to perform core functions of an EIP, (2) proposed operational plan for carrying out the specific objectives of the program, and (3) measures of effectiveness.

Award procedure

Applications that are complete and responsive will be evaluated for scientific and technical merit by an appropriate Objective Review Panel (ORP) in accordance with CDC ORP review policies and procedures. CDC will not review incomplete and non-responsive applications. Complete and responsive applications will undergo a ORP review process, receive a written critique and be scored according to the published review criteria. Successful applicants will receive a Notice of Award (NOA) from the CDC Office of Grants Services. The NOA shall be the only binding, authorizing document between the recipient and CDC. The NOA will be signed by an authorized Grants Management Officer. Initial award provides funds for the first budget period (usually 12 months) and the NOA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. Once competing applicants have been selected by the ORP review process for the first year of funding in the project period, those selected will be eligible to submit annual non-competitive continuation applications for each successive budget period of the project period.

Renewals

Awards under this Program are typically issued for 1- to 5-year project periods. Renewals at the end of each project period are expected to be made available via publishing of a new/continuation NOFO with a complete application and review/award process as described above. Annual renewals within an awarded multi-year project period are made via a non-competitive process and are subject to the availability of funding.

Grant opportunities

Opportunity Status Posted Applications due
Continuing Enhanced National Surveillance for Prion Diseases in the United States CDC-RFA-CK-27-0046 Forecasted —
Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation CDC-RFA-CK-25-0144 Closed
Emerging Infections Program CDC-RFA-CK24-2401 Closed
Emerging Infections Programs CDC-RFA-CK23-2301 Past —
PPHF 2017 _ Epidemiology and Laboratory Capacity (ELC/EIP) _ Emerging Infections Programs _ Primary _ Financed in Part by 2017 Prevention and Public Health Funds CDC-RFA-CK17-1701 Closed
Emerging Infections ProgramNational Center for Emerging and Zoonotic Infectious Diseases CDC-RFA-CK12-120205CONT16 Closed
Research to Advance Vaccine Safety (R01) PA-15-312 Closed
Research to Advance Vaccine Safety (R21) PA-15-313 Closed

Grant awards

Award Recipient Federal obligations Awarded
RFA-IP-24-046: nationwide cohort of blood donors to estimate burden of respiratory viruses and immunologic response U01IP001266 Vitalant $3,700,000
IP24-045, a prospective observational study of respiratory virus epidemiology in the greater boston area U01IP001257 Beth Israel Deaconess Medical Center, Inc. $28,418,915
Connecticut behavioral risk factor surveillance system (CT brfss) NU58DP007841 Department Of Public Health Connecticut $1,117,636
RMI ELC program NU51CK000378 Ministry Of Health In The Repu Blic Of The Marshall Islands $1,052,790
Epidemiology and laboratory capacity for prevention and control of emerging infectious diseases (ELC) - per the ELC… NU51CK000368 City Of New York $7,395,726
Michigan - epidemiology and laboratory capacity for prevention and control of emerging infectious diseases (ELC) - in… NU51CK000362 Michigan Department Of Health And Human Services $1,645,288
Build, strengthen, integrate, and support capacity for epidemiology, laboratory, and health information systems in… NU51CK000352 Idaho Department Of Health & Welfare $2,016,715
Epidemiology and laboratory capacity for prevention and control of emerging infectiousdiseases (ELC) - the oklahoma… NU51CK000348 Oklahoma State Department Of Health $4,255,858
Massachusetts epidemiology and laboratory capacity - this information is provided in the attached ELC application… NU51CK000343 Massachusetts Department Of Public Health $7,053,729
Epidemiology and laboratory capacity for infectious diseases (ELC) - the arkansas department of health will be applying… NU51CK000328 Arkansas Department Of Health $2,846,646

Latest 10 of 46 listed here. See the rest on GovTribe.

Top recipients by federal obligations

10 of 35 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $606,059
FY2025 $16,432,796
FY2024 $283,268,563
FY2023 $106,946,133
FY2022 $100,408,917
FY2021 $66,629,490
FY2020 $187,711,566
FY2019 $110,684,702
FY2018 $44,900,144
FY2017 $38,448,248
FY2016 $1,155,604
FY2015 $303,218
FY2014 $2,400,806
Show all 13

Quick answers

What is Assistance Listing 93.317?

Assistance Listing 93.317 is Emerging Infections Programs, a federal grant program run by Centers for Disease Control and Prevention (Department of Health and Human Services).

What is the CFDA number for Emerging Infections Programs?

Its CFDA number is 93.317: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.317 awarded?

46 grant awards under 93.317 have obligated $2,468,824,899 in federal funds to 35 recipients.

Who receives the most funding from 93.317?

The recipients obligated the most under Emerging Infections Programs are Department Of Public Health Illinois ($506,538,944), Indiana Department Of Health ($398,638,432) and State Of Wisconsin Department Of Health Services ($299,599,456).

How much did 93.317 obligate in fiscal year 2025?

Grants under 93.317 obligated $16,432,796 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.317?

1 listed opportunity under 93.317 is open or forecasted. The latest, Continuing Enhanced National Surveillance for Prion Diseases in the United States, was posted on July 10, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program